Answers are grounded in this paper and cite their sources.
A biotin-modified polyethylene glycol–paclitaxel nanocarrier was developed for the co-delivery of paclitaxel and oxaliplatin in colorectal cancer therapy. The biotin–PEG–PTX copolymer was synthesized and characterized by FTIR spectroscopy, and paclitaxel nanoparticles and oxaliplatin-loaded nanoparticles were prepared through self-assembly. Their physicochemical properties, stability, morphology, and drug-release behavior were evaluated using DLS, TEM, and in vitro release assays. OXA@PTX nanoparticles inhibited HCT-116 cell growth, showed combination-associated cytotoxicity and time-dependent nanoparticle-associated fluorescence, and produced lower macrophage-associated fluorescence than free FITC under the tested conditions. In tumor-bearing mice, the formulation showed qualitatively greater tumor-associated fluorescence, reduced Ki-67 expression, and increased TUNEL staining, with no obvious histopathological abnormalities in major organs. The nanocarrier also exhibited sustained, pH-dependent drug release, supporting its potential as a biotin-functionalized platform for paclitaxel and oxaliplatin co-delivery in colorectal cancer therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: